Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 265,639 shares of the company's stock after purchasing an additional 32,272 shares during the period. Bank of New York Mellon Corp owned approximately 0.47% of Harmony Biosciences worth $9,141,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC lifted its holdings in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after acquiring an additional 965 shares during the last quarter. KBC Group NV lifted its holdings in shares of Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after acquiring an additional 819 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Harmony Biosciences in the 3rd quarter valued at about $74,000. Finally, Avanza Fonder AB bought a new stake in Harmony Biosciences in the fourth quarter worth about $145,000. Hedge funds and other institutional investors own 86.23% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective for the company. HC Wainwright decreased their price objective on shares of Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, February 25th. Finally, Mizuho lifted their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research note on Tuesday. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $53.33.

Insider Activity

In other news, CFO Sandip Kapadia sold 25,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey Dierks sold 1,123 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The disclosure for this sale can be found here. Insiders have sold 72,452 shares of company stock valued at $2,831,679 over the last ninety days. 30.80% of the stock is currently owned by insiders.

Harmony Biosciences Stock Up 1.3 %

NASDAQ HRMY traded up $0.46 on Tuesday, hitting $34.78. The stock had a trading volume of 826,786 shares, compared to its average volume of 514,999. The business's fifty day moving average price is $36.40 and its 200 day moving average price is $35.62. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a 52-week low of $28.14 and a 52-week high of $41.61. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of 16.48, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same period in the previous year, the company earned $0.45 earnings per share. The business's revenue for the quarter was up 19.5% on a year-over-year basis. Equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.